Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 17;16(6):e0253057.
doi: 10.1371/journal.pone.0253057. eCollection 2021.

EA3: A softmax algorithm for evidence appraisal aggregation

Affiliations

EA3: A softmax algorithm for evidence appraisal aggregation

Francesco De Pretis et al. PLoS One. .

Abstract

Real World Evidence (RWE) and its uses are playing a growing role in medical research and inference. Prominently, the 21st Century Cures Act-approved in 2016 by the US Congress-permits the introduction of RWE for the purpose of risk-benefit assessments of medical interventions. However, appraising the quality of RWE and determining its inferential strength are, more often than not, thorny problems, because evidence production methodologies may suffer from multiple imperfections. The problem arises to aggregate multiple appraised imperfections and perform inference with RWE. In this article, we thus develop an evidence appraisal aggregation algorithm called EA3. Our algorithm employs the softmax function-a generalisation of the logistic function to multiple dimensions-which is popular in several fields: statistics, mathematical physics and artificial intelligence. We prove that EA3 has a number of desirable properties for appraising RWE and we show how the aggregated evidence appraisals computed by EA3 can support causal inferences based on RWE within a Bayesian decision making framework. We also discuss features and limitations of our approach and how to overcome some shortcomings. We conclude with a look ahead at the use of RWE.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Behaviour of EA3(c@k,1k@k) for varying β, where β·(1-1k) is the second factor within the scope of the exponential function.
The smaller parameter β and the greater the number of appraisals (the greater k), the closer EA3(c@k,1k@k) gets to the identity map. This graph clearly displays the monotonicity of these functions.
Fig 2
Fig 2. Aggregated appraisals of Karimi et al. (2006) [75] according to De Pretis et al. (2019) [78] (solid line) and EA3 (dash-dot line).
The latter, lower, curve displays the behaviour with respect to the cautiousness parameter β. Both curves agree for β = 0 where EA3 equals the weighted mean.
Fig 3
Fig 3. Similarly to Fig 2, the upper panel shows the aggregated appraisals of Newson et al. (2000) [72], Amberbir et al. (2011) [76] and Beasley et al. (2011) [77] according to De Pretis et al. (2019) [78] (solid line) and EA3 (dash-dot line).
The lower panel depicts the aggregated appraisals for Lesko and Mitchell (1999) [71] and Lesko et al. (2002) [73].
Fig 4
Fig 4. Posterior probability of the causal hypothesis ©, considering Beasley et al. (2011) [77] as evidence E1, and computed in agreement with De Pretis et al. (2019) [78] (solid line) and EA3 (dash-dot, dotted and dashed lines).
For EA3, different lines represent different priors P(E1), whereas the prior P(©) is always set to 1%. All curves agree for νf = 1 where De Pretis et al. (2019) [78] becomes a special case of EA3.
Fig 5
Fig 5. Similarly to Fig 4, the graph pictures the posterior probability of the causal hypothesis ©, considering Beasley et al. (2011) [77] as evidence E1, and computed in agreement with De Pretis et al. (2019) [78] (solid line) and EA3 (dash-dot, dotted and dashed lines).
In this plot, the prior P(©) is set to 0.5%.

Similar articles

Cited by

References

    1. Sherman RE, Anderson SA, Pan GJD, Gray GW, Gross T, Hunter NL, et al.. Real-World Evidence—What Is It and What Can It Tell Us? New England Journal of Medicine. 2016;375(23):2293–2297. doi: 10.1056/NEJMsb1609216 - DOI - PubMed
    1. Audeh B, Calvier FE, Bellet F, Beyens MN, Pariente A, Louet ALL, et al.. Pharmacology and social media: Potentials and biases of web forums for drug mention analysis–case study of France. Health Informatics Journal. 2019;26(2):1253–1272. doi: 10.1177/1460458219865128 - DOI - PubMed
    1. Bolislis WR, Fay M, Kühler TC. Use of Real-world Data for New Drug Applications and Line Extensions. Clinical Therapeutics. 2020;42(5):926–938. doi: 10.1016/j.clinthera.2020.03.006 - DOI - PubMed
    1. Camm A, Coleman C, Tamayo C, Beyer-Westendorf J. Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice. Thrombosis and Haemostasis. 2016;116(S 02):S13–S23. doi: 10.1160/TH16-06-0485 - DOI - PubMed
    1. Cave A, Kurz X, Arlett P. Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. Clinical Pharmacology & Therapeutics. 2019;106(1):36–39. doi: 10.1002/cpt.1426 - DOI - PMC - PubMed

Publication types